Horizon Technology Finance Corporation, a specialty finance company, provides capital in the form of secured loans to venture capital-backed companies in technology, life science, healthcare information, and services, as well as sustainability industries. The company’s investment objective is to maximize its portfolio’s return by generating current income from debt investments and capital appreciation from warrants received during these investments.
Recent updates include:
- Biovaxys and Horizon Technology Finance Corp executed an amendment to their Asset Purchase Agreement on May 29, 2025.
- Horizon Technology Finance Corp executed a First Supplemental Indenture on May 27, 2025.
- The company appointed Michael P. Balkin as Chief Executive Officer, effective June 5, 2025, and announced the retirement of Gerald A. Michaud as President on the same date.
- For the first quarter of 2025, the company provided a portfolio update on April 9, 2025.
- Analysts have varied ratings on the company, with Compass Point downgrading to Sell from Neutral and UBS maintaining a Neutral rating.
The company’s stock is listed on Nasdaq, with a current price of $7.570 USD as of May 30, 2025. The stock has seen a 5-day change of +0.80% and a year-to-date change of -15.80%.
Horizon Technology Finance Corporation is externally managed by Horizon Technology Finance Management LLC. The company’s financial performance and future prospects continue to be monitored by analysts and investors alike.
